Dr Richard Knight and Professor Ruth Roberts are travelling to Boston at the end of August to meet with old colleagues and new contacts, promoting the company’s services in Project Toxicology, Ion Channel Screening and Assay Development, Target Safety Assessments and all aspects of Nonclinical Programme Design. They will be joined by Dr Andrew Winkley.
ApconiX are a team of expert nonclinical drug safety toxicologists and electrophysiologists working with pharmaceutical and biotech companies, governments, universities and research charities worldwide. ApconiX provides cost effective, collaborative support, partnering with clients to make safety a timely, integral part of drug design and enabling rapid and efficient programme progression and ultimately more effective drugs.
Based in Montreal, Andrew Winkley joined ApconiX in July 2019. With over 20 years of industry experience in both pharmaceutical and biotech companies, Andrew has worked at GlaxoSmithKline, AstraZeneca and most recently Vertex Pharmaceuticals in Cambridge Massachusetts.
Greater Boston has the largest concentration of life science researchers in the United States. Home to many of the global leaders, the Kendall Square area of East Cambridge has been described as “the most innovative square mile on the planet”.
Richard worked as a toxicology project leader in oncology and infection at AstraZeneca R&D in Boston for 3 years. “I am really looking forward to catching up with old colleagues and meeting new contacts while we are in Boston. ApconiX has grown significantly in the past 12 months and we have an ambitious growth strategy. The US is, of course, an essential part of that strategy”.